BSX

Boston Scientific
D

BSX

Arincen84/100B

Boston Scientific income statement 1991–2026

21.07B USD over the last twelve months, and 20.07B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
21.07B20.07B16.75B14.24B12.68B11.89B9.91B10.74B9.82B9.05B8.39B
Revenue growth
+8.88%+19.87%+17.61%+12.29%+6.68%+19.92%-7.66%+9.28%+8.57%+7.89%+12.16%
Cost of revenue
6.24B6.22B6.48B5.41B4.97B4.43B4.34B3.86B3.35B3.18B3.04B
Gross profit
14.83B13.85B10.27B8.83B7.71B7.46B5.58B6.88B6.48B5.87B5.34B
Gross margin
70.37%69.01%61.31%62.02%60.83%62.76%56.25%64.08%65.94%64.89%63.71%
Research and development
2.16B2.05B1.62B1.41B1.32B1.20B1.14B1.17B1.11B997.00M920.00M
Selling, general and administrative
7.10B6.89B5.98B5.19B4.52B4.29B3.79B3.93B3.56B3.28B3.08B
Operating expenses
10.39B9.88B7.63B6.65B5.89B5.54B4.98B5.17B4.74B4.35B4.11B
4.44B3.97B2.64B2.18B1.82B1.92B601.00M1.71B1.74B1.53B1.24B
Operating income growth
+32.23%+50.70%+20.82%+19.57%-5.10%+219.80%-64.89%-1.44%+13.90%+23.38%+56.46%
Operating margin
21.05%19.78%15.73%15.32%14.38%16.17%6.06%15.95%17.68%16.85%14.74%
Interest income
——107.00M22.00M10.00M4.00M3.00M30.00M3.00M5.00M5.00M
Interest expense
376.00M349.00M387.00M272.00M464.00M349.00M468.00M513.00M269.00M230.00M234.00M
Other non-operating income
-780.00M-586.00M-353.00M-196.00M-683.00M-846.00M-680.00M-1.03B-315.00M-592.00M-1.06B
Pretax income
3.66B3.39B2.28B1.99B1.14B1.08B-79.00M687.00M1.42B933.00M177.00M
Income tax
163.00M493.00M436.00M393.00M443.00M36.00M2.00M-4.01B-249.00M828.00M-170.00M
Effective tax rate
4.46%14.56%19.11%19.80%38.83%3.35%—-584.13%-17.51%88.75%-96.05%
3.49B2.89B1.85B1.59B698.00M1.04B-82.00M4.70B1.67B104.00M347.00M
Net income growth
+25.18%+55.66%+16.38%+128.22%-32.88%—-101.74%+181.27%+1,506.73%-70.03%—
Net margin
16.56%14.38%11.07%11.19%5.50%8.75%-0.83%43.78%17.01%1.15%4.14%
Basic shares
1.47B1.48B1.47B1.45B1.43B1.42B1.42B1.39B1.38B1.37B1.36B
Diluted shares
1.48B1.49B1.49B1.46B1.44B1.43B1.42B1.41B1.40B1.39B1.38B
Change in diluted shares
-0.91%+0.58%+1.53%+1.65%+0.41%+1.21%+0.43%+0.66%+0.62%+1.13%+2.68%
EPS (basic)
2.371.961.261.080.450.69-0.083.381.210.080.26
EPS (diluted)
2.361.941.251.070.450.69-0.083.331.190.070.25
EPS growth
+26.80%+55.20%+16.52%+140.59%-35.09%—-102.44%+179.99%+1,493.04%-70.12%—
EBITDA
5.41B5.10B3.94B3.45B2.74B2.52B1.51B2.21B2.59B2.01B1.23B
EBITDA margin
25.70%25.42%23.51%24.25%21.61%21.18%15.25%20.60%26.32%22.18%14.62%
EBIT
4.34B3.73B2.67B2.26B1.61B1.43B389.00M1.20B1.69B1.16B411.00M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Boston Scientific's income statement

Source: Financial Modeling Prep